Dr. Nirula is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5171 Meadows del Mar
San Diego, CA 92130Phone+1 858-436-4906
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1997 - 2000
David Geffen School of Medicine at UCLAClass of 1997
Certifications & Licensure
CA State Medical License 1999 - 2025
Awards, Honors, & Recognition
- Fellow (FACR) American College of Rheumatology
Publications & Presentations
PubMed
- The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-...Jonathan I Silverberg, David Rosmarin, Raj Chovatiya, Thomas Bieber, Stephen Schleicher
Nature Communications. 2024-10-25 - Efficacy and Safety of Low-Dose, Rapidly Infused Bamlanivimab and Etesevimab: Phase 3 BLAZE-1 Trial for Mild-to-Moderate COVID-19.Dipak R Patel, Lisa Macpherson, Martin Bohm, Himanshu Upadhyaya, Carmen Deveau
Infectious Diseases and Therapy. 2024-10-01 - Systematic literature review on early clinical evidence for immune-resolution therapies and potential benefits to patients and healthcare providers.Paul Klekotka, Louis Lavoie, Beth Mitchell, Ike Iheanacho, Russel Burge
Frontiers in Immunology. 2024-01-01
Journal Articles
- Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID ‐19 patientsJustin Stebbing Venkatesh Krishnan Stephanie de Bono Silvia Ottaviani Giacomo Casalini Peter J Richardson Vanessa Monteil Volker M Lauschke Ali Mirazimi ..., EMBO Molecular Medicine
Authored Content
- A Phase 2 Trial of Peresolimab for Adults with Rheumatoid ArthritisOctober 2022
Press Mentions
Drug May Offer New Approach Against Rheumatoid ArthritisMay 18th, 2023- Lilly's Peresolimab Phase 2a Rheumatoid Arthritis Trial Published in the New England Journal of MedicineMay 18th, 2023
- Artax Biopharma Expands Company's Scientific Advisory BoardNovember 15th, 2022
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
